PDCD1 and breast cancer: Many clinical trials had proved that immune checkpoint inhibitors (ICIs) against programmed cell death protein-1(PD-1)/programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) axes can induce durable clinical responses in some BC patients (4).